Abstract
BackgroundPancreatic ductal adenocarcinoma (PDAC) is one of the most malignant cancers worldwide. Despite the promising outcome of immune checkpoint inhibitors and agonist antibody therapies in different malignancies, PDAC exhibits high...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have